Alzamend Neuro: Can $711K Cash Survive an $8M Burn? FY2026 Audit Analysis

An independent forensic financial and strategic audit of Alzamend Neuro, Inc. (Nasdaq: ALZN) based on FY2026 disclosures. We analyze the 32-day cash runway, the frozen ALZN002 cell therapy pipeline, $1.9M in CRO litigation costs, toxic warrant anti-dilution ratchets, and executive cross-affiliations with Hyperscale Data. If you need the complete, high-density strategic presentation PDF with all the raw financial tables and segment breakdowns, send an email to [email protected] or click the link in the description at https://www.hdinresearch.com/news/1718. Make sure to subscribe to @hdin230; #AlzamendNeuro #BiotechAudit #ALZN #NasdaqListingDeficit #ClinicalTrialAnalysis #MicroCapForensics #HDINResearch